reweave: merge 10 files via frontmatter union [auto]
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
This commit is contained in:
parent
5bcdfd12df
commit
782560ac8f
10 changed files with 56 additions and 9 deletions
|
|
@ -10,7 +10,13 @@ agent: theseus
|
|||
sourced_from: ai-alignment/2026-01-09-dod-ai-strategy-any-lawful-use-mandate-hegseth.md
|
||||
scope: structural
|
||||
sourcer: Sealevel Systems
|
||||
related: ["dod-any-lawful-use-mandate-structurally-eliminates-vendor-safety-restrictions", "open-weight-release-bypasses-vendor-restriction-negotiation"]
|
||||
related:
|
||||
- dod-any-lawful-use-mandate-structurally-eliminates-vendor-safety-restrictions
|
||||
- open-weight-release-bypasses-vendor-restriction-negotiation
|
||||
supports:
|
||||
- Pentagon endorsement of open-weight models for IL7 classified networks reveals DoD architectural preference for deployment models with minimal alignment governance over safety-constrained proprietary systems
|
||||
reweave_edges:
|
||||
- Pentagon endorsement of open-weight models for IL7 classified networks reveals DoD architectural preference for deployment models with minimal alignment governance over safety-constrained proprietary systems|supports|2026-05-09
|
||||
---
|
||||
|
||||
# Open-weight AI model release bypasses 'any lawful use' contract negotiation entirely by eliminating the vendor relationship, enabling DoD to inspect and modify internal architecture without contractual restrictions
|
||||
|
|
@ -22,4 +28,4 @@ NVIDIA's IL7 deal and Reflection AI's open-weight commitment represent a separat
|
|||
|
||||
**Source:** Breaking Defense, DefenseScoop - Reflection AI IL7 endorsement
|
||||
|
||||
Pentagon granted IL7 (highly restricted) classified network access to Reflection AI, an open-weight model startup explicitly positioned as the 'American DeepSeek.' Open-weight architecture means public weights, no centralized deployment control, and no vendor-imposed alignment governance. This demonstrates that open-weight release not only bypasses vendor restrictions but is actively preferred by DoD for classified deployments over safety-constrained proprietary systems.
|
||||
Pentagon granted IL7 (highly restricted) classified network access to Reflection AI, an open-weight model startup explicitly positioned as the 'American DeepSeek.' Open-weight architecture means public weights, no centralized deployment control, and no vendor-imposed alignment governance. This demonstrates that open-weight release not only bypasses vendor restrictions but is actively preferred by DoD for classified deployments over safety-constrained proprietary systems.
|
||||
|
|
@ -10,9 +10,18 @@ agent: clay
|
|||
scope: structural
|
||||
sourcer: a16z crypto
|
||||
related_claims: ["[[community-owned-IP-has-structural-advantage-in-human-made-premium-because-provenance-is-inherent-and-legible]]", "[[fanchise management is a stack of increasing fan engagement from content extensions through co-creation and co-ownership]]"]
|
||||
related: ["community-owned-ip-is-community-branded-but-not-community-governed-in-flagship-web3-projects", "external-showrunner-partnerships-complicate-community-ip-editorial-authority-by-splitting-creative-control-between-founding-team-and-studio-professionals", "NFT holder royalties from IP licensing create permanent financial skin-in-the-game that aligns holder interests with IP quality without requiring governance participation", "community-owned-ip-theory-preserves-concentrated-creative-execution-through-strategic-operational-separation"]
|
||||
reweave_edges: ["community-owned-ip-is-community-branded-but-not-community-governed-in-flagship-web3-projects|related|2026-04-17", "external-showrunner-partnerships-complicate-community-ip-editorial-authority-by-splitting-creative-control-between-founding-team-and-studio-professionals|related|2026-04-17", "NFT holder royalties from IP licensing create permanent financial skin-in-the-game that aligns holder interests with IP quality without requiring governance participation|related|2026-04-17"]
|
||||
related:
|
||||
- community-owned-ip-is-community-branded-but-not-community-governed-in-flagship-web3-projects
|
||||
- external-showrunner-partnerships-complicate-community-ip-editorial-authority-by-splitting-creative-control-between-founding-team-and-studio-professionals
|
||||
- NFT holder royalties from IP licensing create permanent financial skin-in-the-game that aligns holder interests with IP quality without requiring governance participation
|
||||
- community-owned-ip-theory-preserves-concentrated-creative-execution-through-strategic-operational-separation
|
||||
reweave_edges:
|
||||
- community-owned-ip-is-community-branded-but-not-community-governed-in-flagship-web3-projects|related|2026-04-17
|
||||
- external-showrunner-partnerships-complicate-community-ip-editorial-authority-by-splitting-creative-control-between-founding-team-and-studio-professionals|related|2026-04-17
|
||||
- NFT holder royalties from IP licensing create permanent financial skin-in-the-game that aligns holder interests with IP quality without requiring governance participation|related|2026-04-17
|
||||
sourced_from: ["inbox/archive/entertainment/2026-04-12-a16z-community-owned-characters-framework.md"]
|
||||
supports:
|
||||
- Community IP governance fragmentation increases with liquidity as tradable ownership attracts financially-motivated holders with weaker creative alignment
|
||||
---
|
||||
|
||||
# Community-owned IP theory preserves concentrated creative execution by separating strategic funding decisions from operational creative development
|
||||
|
|
@ -27,4 +36,4 @@ The framework proposes that economic alignment through NFT royalties creates suf
|
|||
|
||||
**Source:** AWN/Mediawan partnership structure, April 2026
|
||||
|
||||
The Mediawan co-production structure shows how community-validated IP can access institutional production capital while preserving IP ownership. Claynosaurz retains IP rights; Mediawan provides production financing and expertise. This is structurally different from traditional studio acquisition deals where IP transfers to the studio. The co-production model enables institutional-scale production (40 episodes, major European producer) without surrendering IP governance or community relationship.
|
||||
The Mediawan co-production structure shows how community-validated IP can access institutional production capital while preserving IP ownership. Claynosaurz retains IP rights; Mediawan provides production financing and expertise. This is structurally different from traditional studio acquisition deals where IP transfers to the studio. The co-production model enables institutional-scale production (40 episodes, major European producer) without surrendering IP governance or community relationship.
|
||||
|
|
@ -10,7 +10,15 @@ agent: vida
|
|||
sourced_from: health/2026-05-08-glp1-bbb-penetrance-neuroprotection-holscher-2024.md
|
||||
scope: causal
|
||||
sourcer: Holscher C.
|
||||
related: ["glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure"]
|
||||
related:
|
||||
- glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials
|
||||
- glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure
|
||||
supports:
|
||||
- GLP-1 Parkinson's efficacy divergence between lixisenatide Phase 2 success and exenatide Phase 3 failure suggests disease stage and regional CNS penetrance are confounding variables not captured by class-level analysis
|
||||
- Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability
|
||||
reweave_edges:
|
||||
- GLP-1 Parkinson's efficacy divergence between lixisenatide Phase 2 success and exenatide Phase 3 failure suggests disease stage and regional CNS penetrance are confounding variables not captured by class-level analysis|supports|2026-05-09
|
||||
- Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability|supports|2026-05-09
|
||||
---
|
||||
|
||||
# GLP-1 neuroprotective effects in Parkinson's disease require regional CNS penetrance to the substantia nigra, not just blood-brain barrier crossing
|
||||
|
|
@ -22,4 +30,4 @@ Holscher's 2024 review proposed that GLP-1 agonists' neuroprotective effects cor
|
|||
|
||||
**Source:** LIXIPARK NEJM 2024, Holscher 2024 PMC review
|
||||
|
||||
Lixisenatide (identified by Holscher 2024 as having strongest neuroprotective effect via adsorption transcytosis BBB penetrance) succeeded in LIXIPARK Phase 2 for early Parkinson's, while exenatide (which reached CNS but not substantia nigra per Phase 3 CSF analysis) failed. This drug-specific divergence in the same indication supports the claim that regional CNS penetrance, not just BBB crossing, determines neuroprotective efficacy.
|
||||
Lixisenatide (identified by Holscher 2024 as having strongest neuroprotective effect via adsorption transcytosis BBB penetrance) succeeded in LIXIPARK Phase 2 for early Parkinson's, while exenatide (which reached CNS but not substantia nigra per Phase 3 CSF analysis) failed. This drug-specific divergence in the same indication supports the claim that regional CNS penetrance, not just BBB crossing, determines neuroprotective efficacy.
|
||||
|
|
@ -5,6 +5,10 @@ domain: health
|
|||
created: 2026-02-17
|
||||
source: "HHS Surgeon General social connection advisory 2023; National Academies social isolation Medicare cost 2023; Lancet Public Health social prescribing landscape US 2025; Mass Cultural Council CultureRx ROI data"
|
||||
confidence: likely
|
||||
supports:
|
||||
- Loneliness increases dementia risk by 50 percent independently of depression and cardiovascular disease making social connection the highest-leverage non-pharmacological dementia prevention strategy
|
||||
reweave_edges:
|
||||
- Loneliness increases dementia risk by 50 percent independently of depression and cardiovascular disease making social connection the highest-leverage non-pharmacological dementia prevention strategy|supports|2026-05-09
|
||||
---
|
||||
|
||||
# social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem
|
||||
|
|
@ -48,4 +52,4 @@ Relevant Notes:
|
|||
- Devoted democratizes VIP-level care by assigning every member a hybrid AI-human care team with digital twins and hundreds of daily interactions -- Devoted's care model explicitly includes loneliness reduction as a care function, addressing the $6.7B cost driver through persistent human+AI connection
|
||||
|
||||
Topics:
|
||||
- health and wellness
|
||||
- health and wellness
|
||||
|
|
@ -22,11 +22,13 @@ related:
|
|||
- bipartisan-prediction-market-legislation-threatens-cftc-preemption-through-congressional-redefinition
|
||||
- dcm-field-preemption-protects-all-contracts-on-registered-platforms-regardless-of-type
|
||||
- Tribal gaming IGRA exclusivity creates federal prediction market enforcement pathway independent of Dodd-Frank preemption
|
||||
- Prediction Market Act 2026
|
||||
supports:
|
||||
- Bipartisan state AG coalition of 38 jurisdictions signals near-consensus government opposition to CFTC prediction market preemption through federalism arguments that transcend partisan alignment
|
||||
reweave_edges:
|
||||
- Bipartisan state AG coalition of 38 jurisdictions signals near-consensus government opposition to CFTC prediction market preemption through federalism arguments that transcend partisan alignment|supports|2026-04-27
|
||||
- Tribal gaming IGRA exclusivity creates federal prediction market enforcement pathway independent of Dodd-Frank preemption|related|2026-04-28
|
||||
- Prediction Market Act 2026|related|2026-05-09
|
||||
---
|
||||
|
||||
# Bipartisan Senate legislation to reclassify prediction market sports contracts as gambling threatens CFTC preemption through Congressional redefinition rather than judicial interpretation
|
||||
|
|
@ -58,4 +60,4 @@ Sens. Curtis (R-UT) and Schiff (D-CA) introduced 'Prediction Markets Are Gamblin
|
|||
|
||||
**Source:** McCormick-Gillibrand bill, April 30, 2026
|
||||
|
||||
The Prediction Market Act of 2026 (McCormick-Gillibrand) represents the first bipartisan statutory attempt to define event contracts, creating a potential legislative override of the current CFTC regulatory framework. The bill establishes comprehensive federal framework including enhanced DCM certification standards, Office of the Retail Advocate within CFTC, and Advisory Council on Consumer Protection. This is a qualitatively different approach than the Blumenthal 'Prediction Markets Security and Integrity Act' (more restrictive), suggesting multiple competing legislative visions for prediction market regulation.
|
||||
The Prediction Market Act of 2026 (McCormick-Gillibrand) represents the first bipartisan statutory attempt to define event contracts, creating a potential legislative override of the current CFTC regulatory framework. The bill establishes comprehensive federal framework including enhanced DCM certification standards, Office of the Retail Advocate within CFTC, and Advisory Council on Consumer Protection. This is a qualitatively different approach than the Blumenthal 'Prediction Markets Security and Integrity Act' (more restrictive), suggesting multiple competing legislative visions for prediction market regulation.
|
||||
|
|
@ -10,10 +10,12 @@ supports:
|
|||
related:
|
||||
- the SECs Transition Point mechanism creates a competitive incentive for token projects to decentralize because decentralization is now a formal pathway to reduced regulatory burden
|
||||
- the SECs distinction between the crypto asset and the investment contract means tokens are not inherently securities and only the surrounding transaction structure can create securities obligations
|
||||
- SEC binary options approval validates outcome-linked instruments while states fight prediction markets
|
||||
reweave_edges:
|
||||
- SEC Token Taxonomy Framework (2026)|supports|2026-04-19
|
||||
- the SECs Transition Point mechanism creates a competitive incentive for token projects to decentralize because decentralization is now a formal pathway to reduced regulatory burden|related|2026-04-19
|
||||
- the SECs distinction between the crypto asset and the investment contract means tokens are not inherently securities and only the surrounding transaction structure can create securities obligations|related|2026-04-19
|
||||
- SEC binary options approval validates outcome-linked instruments while states fight prediction markets|related|2026-05-09
|
||||
sourced_from:
|
||||
- inbox/archive/internet-finance/2026-03-17-sec-cftc-token-taxonomy-interpretation.md
|
||||
---
|
||||
|
|
|
|||
|
|
@ -17,6 +17,7 @@ reweave_edges:
|
|||
- Google's Project Suncatcher research identifies $200/kg launch cost as the enabling threshold for gigawatt-scale orbital AI compute constellations, validating the tier-specific model where constellation-scale ODC requires Starship-class economics while proof-of-concept operates on Falcon 9|supports|2026-04-11
|
||||
- Orbital AI data centers face a decade-long cost parity gap with terrestrial compute because radiation hardening, latency, and launch economics favor Earth-based infrastructure through at least the mid-2030s|supports|2026-05-01
|
||||
- "Orbital AI data centers face four engineering gaps with no demonstrated solutions: radiation hardening at compute density scale, thermal management in vacuum, in-orbit repair infeasibility, and continuous power availability in LEO|supports|2026-05-05"
|
||||
- Terafab 80 percent orbital compute allocation creates semiconductor demand driver dependent on unproven radiation hardening and thermal management|supports|2026-05-09
|
||||
related:
|
||||
- orbital compute hardware cannot be serviced making every component either radiation-hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit
|
||||
- google-project-suncatcher
|
||||
|
|
@ -24,6 +25,7 @@ supports:
|
|||
- Google's Project Suncatcher research identifies $200/kg launch cost as the enabling threshold for gigawatt-scale orbital AI compute constellations, validating the tier-specific model where constellation-scale ODC requires Starship-class economics while proof-of-concept operates on Falcon 9
|
||||
- Orbital AI data centers face a decade-long cost parity gap with terrestrial compute because radiation hardening, latency, and launch economics favor Earth-based infrastructure through at least the mid-2030s
|
||||
- "Orbital AI data centers face four engineering gaps with no demonstrated solutions: radiation hardening at compute density scale, thermal management in vacuum, in-orbit repair infeasibility, and continuous power availability in LEO"
|
||||
- Terafab 80 percent orbital compute allocation creates semiconductor demand driver dependent on unproven radiation hardening and thermal management
|
||||
sourced_from:
|
||||
- inbox/archive/2026-02-17-astra-space-data-centers-research.md
|
||||
---
|
||||
|
|
|
|||
|
|
@ -15,6 +15,9 @@ reweave_edges:
|
|||
- space debris removal is becoming a required infrastructure service as every new constellation increases collision risk toward Kessler syndrome|supports|2026-04-04
|
||||
- space traffic management is the most urgent governance gap because no authority has binding power to coordinate collision avoidance among thousands of operators|supports|2026-04-04
|
||||
- FCC Chair Carr's rebuke of Amazon's orbital debris objections applies competitive market logic to a commons governance problem, treating Kessler Syndrome risk as a competitive standing question rather than a planetary externality|supports|2026-05-06
|
||||
- The CRASH clock compressed from 121 days in 2018 to 2.5 days in May 2026 at an accelerating rate of 0.5 days per month in 2026 providing quantitative evidence that LEO collision risk is increasing faster than governance mechanisms are responding|related|2026-05-09
|
||||
related:
|
||||
- The CRASH clock compressed from 121 days in 2018 to 2.5 days in May 2026 at an accelerating rate of 0.5 days per month in 2026 providing quantitative evidence that LEO collision risk is increasing faster than governance mechanisms are responding
|
||||
---
|
||||
|
||||
# orbital debris is a classic commons tragedy where individual launch incentives are private but collision risk is externalized to all operators
|
||||
|
|
|
|||
|
|
@ -10,6 +10,10 @@ key_people:
|
|||
- David Ellison (CEO)
|
||||
website:
|
||||
tags: [studio, ai-production, merger, streaming]
|
||||
supports:
|
||||
- The IP accumulation path achieved structural DTC profitability in 2026, demonstrating it is a viable long-term configuration not a declining model
|
||||
reweave_edges:
|
||||
- The IP accumulation path achieved structural DTC profitability in 2026, demonstrating it is a viable long-term configuration not a declining model|supports|2026-05-09
|
||||
---
|
||||
|
||||
# Paramount Skydance (PSKY)
|
||||
|
|
|
|||
|
|
@ -4,6 +4,13 @@ entity_type: research_program
|
|||
name: Exenatide-PD3 Trial
|
||||
domain: health
|
||||
status: completed
|
||||
supports:
|
||||
- GLP-1 Parkinson's efficacy divergence between lixisenatide Phase 2 success and exenatide Phase 3 failure suggests disease stage and regional CNS penetrance are confounding variables not captured by class-level analysis
|
||||
related:
|
||||
- Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability
|
||||
reweave_edges:
|
||||
- GLP-1 Parkinson's efficacy divergence between lixisenatide Phase 2 success and exenatide Phase 3 failure suggests disease stage and regional CNS penetrance are confounding variables not captured by class-level analysis|supports|2026-05-09
|
||||
- Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability|related|2026-05-09
|
||||
---
|
||||
|
||||
# Exenatide-PD3 Trial
|
||||
|
|
|
|||
Loading…
Reference in a new issue